Compass Therapeutics Reports $14.3 Million Net Loss in Q3 2025, Total Assets Rise to $231.3 Million

Compass Therapeutics, Inc. reported its financial results for the third quarter and the first nine months of 2025, revealing a net loss of $14.3 million for the three months ending September 30, 2025, compared to a loss of $10.5 million for the same period in 2024. For the nine-month period, the company recorded a net loss of $50.8 million, up from $34.3 million in the prior year. The increase in losses is attributed primarily to a 49% rise in research and development expenses, which totaled $12.8 million for the quarter and $42.3 million for the nine months, reflecting ongoing investments in clinical trials and product development.

The company did not generate any licensing revenue during the third quarter or the nine months ended September 30, 2025, a significant decrease from the $850,000 reported in the same period last year. This decline was primarily due to the absence of milestone payments from collaborations, which had previously contributed to revenue. Operating expenses for the third quarter totaled $15.8 million, an increase from $12.2 million in the prior year, driven by higher research and development costs associated with new pipeline candidates, particularly CTX-10726.

In terms of financial position, Compass Therapeutics reported total assets of $231.3 million as of September 30, 2025, a substantial increase from $140.4 million at the end of 2024. This growth was largely fueled by a successful equity offering in August 2025, which raised approximately $129.3 million in net proceeds. The company’s cash, cash equivalents, and marketable securities stood at $220 million, which management believes will support operations through 2028. The total stockholders' equity also rose to $209.6 million, up from $125.2 million at the end of 2024.

Operationally, Compass Therapeutics is advancing its clinical pipeline, which includes three product candidates in clinical trials and one in IND-enabling studies. The company is focusing on its lead candidate, tovecimig, and expects to report data from a Phase 2/3 study in patients with biliary tract cancer in late Q1 2026. Additionally, the company is preparing to expand its clinical studies for CTX-8371 based on encouraging responses observed in earlier cohorts. As of September 30, 2025, the company had 177.6 million shares outstanding, reflecting the impact of its recent equity financing.

Looking ahead, Compass Therapeutics anticipates continued significant operating losses as it invests in the development of its product candidates. The company acknowledges the need for additional funding to support its growth strategy, which may include further equity or debt financing, collaborations, or strategic partnerships. The management remains optimistic about the potential of its pipeline but recognizes the inherent risks and uncertainties associated with drug development and commercialization.